5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine,
SB2343,
VS-5584,
VS-5584,
1246560-33-7,
5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine,
VS-5584 (SB2343),
SB2343,
UNII-W71J4X250V,
SB-2343,
CHEMBL3393066,
W71J4X250V,
5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine,
C17H22N8O,
2-Pyrimidinamine, 5-(8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl)-,
2-Pyrimidinamine, 5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-,
QYBGBLQCOOISAR-UHFFFAOYSA-N,
5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine,
SCHEMBL539098,
GTPL8382,
vs-5584-sb2343,
DTXSID10677328,
EX-A288,
HMS3652B16,
BCP08247,
2797AH,
BDBM50059635,
MFCD25372027,
s7016,
VS5584,
ZINC95644685,
AKOS024465057,
CS-1202,
DB12986,
SB 2343,
SB16877,
NCGC00386370-03,
NCGC00386370-06,
AK163764,
BC600432,
DA-46738,
DA-46740,
HY-16585,
AB0165544,
AX8294897,
FT-0700143,
SW220201-1,
A12480,
W-6043,
J-690096,
5-[9-Isopropyl-8-methyl-2-(morpholin-4-yl)purin-6-yl]pyrimidin-2-amine,
5-[8-Methyl-2-(morpholin-4-yl)-9-(propan-2-yl)-9H-purin-6-yl]pyrimidin-2-amine,
SB-2343|||5-(8-Methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine,
D01EUD,
D0U3DP,
ACN-029553,
SB-2312,
MPI-0479605,
A3927,
C585120,
MTOR/PI3K alpha dual inhibitors (cancer), S*BIO,
(S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate,
1246529-32-7,
Mammalian target of rapamycin/phosphoinositide 3 kinase alpha dual inhibitors (cancer), S*Bio,